Recently, several case studies have suggested that anti-PD-1/PD-L1 monoclonal antibodies might trigger disorders of the coagulation-fibrinolysis system in advanced cancer patients, which implies that the systemic immune activation may impact a balance between clotting and bleeding [13,14,21,22,23]. The gene discussed is CD274; the disease is cancer.